1-20 of 23
Naveen Garg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Nitin Jain, Philip Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati, Koichi Takahashi, Mahesh Swaminathan, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju, Koji Sasaki, Divyam Bansal, Marina Y. Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Wei Wang, Sa A. Wang, Jeffrey L. Jorgensen, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3267.
https://doi.org/10.1182/blood-2023-188084
Published: 2023
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Mahesh Swaminathan, Koichi Takahashi, Zeev Estrov, Marina Y. Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado Valero, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A. Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 4635.
https://doi.org/10.1182/blood-2023-189711
Published: 2023
Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 238–240.
https://doi.org/10.1182/blood-2022-170030
Published: 2022
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Marina Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 234–237.
https://doi.org/10.1182/blood-2022-170850
Published: 2022
Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, Alessandra Ferrajoli, Musa Yilmaz, Philip A. Thompson, Marina Konopleva, Michael R Green, Deepa Sampath, Sattva S. Neelapu, Koichi Takahashi, Lucia Masarova, Jan A. Burger, Rashmi Kanagal-Shamanna, Joseph D. Khoury, Naveen Garg, Xiaoping Su, Xuemei Wang, Hinalben Patel, Ana Ayala, Hagop Kantarjian, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 2626.
https://doi.org/10.1182/blood-2021-154195
Published: 2021
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3720.
https://doi.org/10.1182/blood-2021-154454
Published: 2021
Journal Articles

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Philip A. Thompson, Yan Wang, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3723.
https://doi.org/10.1182/blood-2021-149919
Published: 2021
Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Nitin Jain, Alessandra Ferrajoli, Philip A. Thompson, Marina Konopleva, Michael R Green, Deepa Sampath, Sattva S. Neelapu, Koichi Takahashi, Paolo Strati, Jan A. Burger, Rashmi Kanagal-Shamanna, Joseph D. Khoury, Naveen Garg, Xiaoping Su, Xuemei Wang, Hinalben Patel, Ana Ayala, Hagop Kantarjian, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 1550.
https://doi.org/10.1182/blood-2021-154279
Published: 2021
Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-141716
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 34.
https://doi.org/10.1182/blood-2019-131847
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 357.
https://doi.org/10.1182/blood-2019-131939
Published: 2019
Journal Articles

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Prithviraj Bose, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSc, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 359.
https://doi.org/10.1182/blood-2019-131732
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev E. Estrov, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 695.
https://doi.org/10.1182/blood-2018-185
Published: 2018
Journal Articles

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro N. Ohanian, DO, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 696.
https://doi.org/10.1182/blood-2018-186
Published: 2018
Journal Articles

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Clinical Trials & Observations
Mani Akhtari, Sarah A. Milgrom, Chelsea C. Pinnix, Jay P. Reddy, Wenli Dong, Grace L. Smith, Osama Mawlawi, Zeinab Abou Yehia, Jillian Gunther, Eleanor M. Osborne, Therese Y. Andraos, Christine F. Wogan, Eric Rohren, Naveen Garg, Hubert Chuang, Joseph D. Khoury, Yasuhiro Oki, Michelle Fanale, Bouthaina S. Dabaja
Journal: Blood
Blood (2018) 131 (1): 84–94.
https://doi.org/10.1182/blood-2017-04-773838
Published: 2018
Journal Articles

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

Nitin Jain, MD, Philip A Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD, Prithviraj Bose, MD, Zeev Estrov, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Tapan Kadia, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Maro Ohanian, DO, Jorge E. Cortes, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Naveen Garg, MD, Xuemei Wang, Nina Fru, RN, Nichole Cruz, RN, Varsha Gandhi, PhD, William Plunkett, PhD, Hagop M. Kantarjian, MD, Michael J. Keating, MD, William G Wierda, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 429.
https://doi.org/10.1182/blood.V130.Suppl_1.429.429
Published: 2017
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A Thompson, MBBS, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, Varsha Gandhi, PhD, William Plunkett, PhD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, William G Wierda, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 495.
https://doi.org/10.1182/blood.V130.Suppl_1.495.495
Published: 2017
Journal Articles

Outcomes of Venous Thromboembolism (VTE) Treatment in Thrombocytopenic Leukemic Patients

Maliha Khan, MD, Mohammed Nassif, Mohanad Alzubaidi, Travis Cox, Thein H. Oo, MD, Naveen Garg, Cristhiam Mauricio Rojas-Hernandez
Journal: Blood
Blood (2016) 128 (22): 4964.
https://doi.org/10.1182/blood.V128.22.4964.4964
Published: 2016
Journal Articles

High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial

Dai Chihara, MD PhD, Yasuhiro Oki, MD, Jason R Westin, MD, Loretta Nastoupil, MD, Luis E. Fayad, MD, Felipe Samaniego, MD, Emily Wesson, APN, Charnelle Ruben, BS, Sandra B. Horowitz, PharmD, Lei Feng, MS, Naveen Garg, Sairah Ahmed, MD, Issa F. Khouri, Chitra M. Hosing, MD, Jorge E. Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD
Journal: Blood
Blood (2015) 126 (23): 3987.
https://doi.org/10.1182/blood.V126.23.3987.3987
Published: 2015